Prognostic value of intraductal carcinoma for adjuvant radiotherapy candidates after radical prostatectomy

Int J Clin Pract. 2021 Jun;75(6):e14099. doi: 10.1111/ijcp.14099. Epub 2021 Mar 8.

Abstract

Objective: To investigate the prognostic significance of intraductal carcinoma of the prostate (IDC-P) in radical prostatectomy (RP) specimens and predictive value of IDC-P for biochemical recurrence and adjuvant therapy decision.

Method: We retrospectively evaluated patients who were performed RP between 2000 and 2014. Among, 67 patients who had stage pT3a tumour with negative surgical margin (Group 1, n = 35) and who had stage pT2 tumour with positive surgical margin (Group 2, n = 32) were included in the study. RP specimens were re-evaluated for the presence of IDC-P component and other prognostic factors. In both the groups, prognostic factors were compared according to the presence of IDC-P and biochemical recurrence status.

Results: In Group 1, IDC-P was detected in five cases and biochemical recurrence was detected in three cases. Patients with IDC-P showed significantly higher biochemical recurrence than those without IDC-P (P = .002). In univariate analysis, IDC-P was found to be significantly associated with worse progression-free survival (P < .001). In Group 2, IDC-P was detected in four cases and biochemical recurrence was detected in 10 cases. Also, tumour volume was significantly higher in patients with IDC-P than those without IDC-P (P = .02). IDC-P was also significantly associated with worse progression-free survival in Group 2 (P = .033).

Conclusions: In both the groups, IDC-P was a prognostic factor for progression-free survival and/or biochemical recurrence. Especially in these patients, the presence of IDC-P might be helpful for postoperative adjuvant therapy management decision.

MeSH terms

  • Carcinoma, Intraductal, Noninfiltrating* / surgery
  • Humans
  • Male
  • Neoplasm Recurrence, Local
  • Prognosis
  • Prostate
  • Prostate-Specific Antigen
  • Prostatectomy
  • Prostatic Neoplasms* / radiotherapy
  • Prostatic Neoplasms* / surgery
  • Radiotherapy, Adjuvant
  • Retrospective Studies

Substances

  • Prostate-Specific Antigen